CIK 0002123613 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Kardigan, Inc.
Sign in to watch- Ticker
- KARD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 932994203
- Phone
- (415) 573-3220
- Business address
- C/O KARDIGAN, INC., 131 OYSTER POINT BLVD., SECOND FLOOR, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-17 | BERNS PAUL L Director | Grant or award | +20,706 | 20,706 | ||
| 2026-06-17 | BERNS PAUL L Director | Conversion · Series A Preferred Stock | −5,148,587 | 0 | ||
| 2026-06-17 | BERNS PAUL L Director | Conversion · Series B Preferred Stock | −1,204,000 | 0 | ||
| 2026-06-17 | BERNS PAUL L Director | Conversion · Series B-1 Preferred Stock | −2,306,401 | 0 | ||
| 2026-06-17 | Moriarty John B Chief Legal Officer | Grant or award | +47,784 | 47,784 | ||
| 2026-06-17 | Jahn Brianne Chief Financial Officer | Grant or award | +79,640 | 79,640 | ||
| 2026-06-17 | Popovits Kimberly J Director | Grant or award | +20,706 | 20,706 | ||
| 2026-06-17 | Walbert Timothy P Director | Grant or award | +20,706 | 20,706 | ||
| 2026-06-17 | Walbert Timothy P Director | Grant or award · Stock Option (Right to Buy) | +57,573 | 57,573 | ||
| 2026-06-17 | GIANAKAKOS ANASTASIOS President & CEO | Conversion | +28,702 | 5,665,090 | ||
| 2026-06-17 | GIANAKAKOS ANASTASIOS President & CEO | Conversion | +41,001 | 2,422,520 | ||
| 2026-06-17 | GIANAKAKOS ANASTASIOS President & CEO | Conversion | +498,692 | 498,692 | ||
| 2026-06-17 | GIANAKAKOS ANASTASIOS President & CEO | Conversion · Series A Preferred Stock | −18,020 | 0 | ||
| 2026-06-17 | GIANAKAKOS ANASTASIOS President & CEO | Conversion · Series A Preferred Stock | −25,742 | 0 | ||
| 2026-06-17 | GIANAKAKOS ANASTASIOS President & CEO | Conversion · Series B Preferred Stock | −313,092 | 0 | ||
| 2026-06-17 | Giordano Douglas E. Director | Grant or award | +20,706 | 20,706 | ||
| 2026-06-17 | Edelberg Jay Chief Medical Officer | Conversion | +97,587 | 135,543 | ||
| 2026-06-17 | Edelberg Jay Chief Medical Officer | Grant or award | +47,784 | 183,327 | ||
| 2026-06-17 | Edelberg Jay Chief Medical Officer | Conversion · Series B Preferred Stock | −61,268 | 0 |
Page 2 of 2 · 39 trades